New diabetes drug passes first safety check in healthy men
NCT ID NCT06284798
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tested a new medicine called NNC0650-0013 in 11 healthy men to see if it is safe and how the body processes it. The drug is being developed for type 2 diabetes. Participants received a single injection under the skin or into a vein, and some got a placebo. The study lasted up to 17 weeks and focused on side effects and drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NNC0650-0013
- What this could lead to
- If successful, this could lead to a new treatment option for type 2 diabetes.
- What could go wrong
- This is a very early, small study in healthy people, not those with diabetes. The drug may not work or may have safety issues in later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Profil Institut für Stoffwechselforschung GmbH
Neuss, 41460, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates